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Key regulatory genes, suppressed by Polycomb and
H3K27me3, become active during normal differentia-
tion and induced reprogramming. Using the well-
characterized enhancer/promoter pair of MYOD1 as
a model, we have identified a critical role for
enhancers in reprogramming. We observed an unex-
pected nucleosome-depleted region (NDR) at the
H3K4me1-enriched enhancer at which transcrip-
tional regulators initially bind, leading to subsequent
changes in the chromatin at the cognate promoter.
Exogenous Myod1 activates its own transcription
by binding first at the enhancer, leading to an NDR
and transcription-permissive chromatin at the asso-
ciated MYOD1 promoter. Exogenous OCT4 also
binds first to the permissive MYOD1 enhancer but
has a different effect on the cognate promoter, where
the monovalent H3K27me3 marks are converted to
the bivalent state characteristic of stem cells.
Genome-wide, a high percentage of Polycomb
targets are associated with putative enhancers in
permissive states, suggesting that they may provide
a widespread avenue for the initiation of cell-fate re-
programming.INTRODUCTION
Epigenetic mechanisms regulate genomic output in normal
tissue and are implicated in reprogramming (Maherali et al.,
2007; Rideout et al., 2001). The roles of DNA methylation and
histone modifications have been extensively studied in promoter
regulation, whereas the significance of nucleosome occupancy
is increasingly being recognized (Hinshelwood et al., 2009; Kelly
et al., 2010; Lin et al., 2007; Wolff et al., 2010; You et al., 2011).
Distal regulatory regions such as enhancers also play importantroles in regulating gene expression, though it has been difficult to
identify enhancer/promoter pairs since they can be located at
varied distances from transcriptional start sites (TSS) or act in
trans (Atchison and Perry, 1988). Epigenome-wide studies
have begun to establish chromatin signatures of active
enhancers, which are DNase hypersensitive (Xi et al., 2007),
have a moderate association with p300 (Heintzman et al.,
2007; Visel et al., 2009; Wang et al., 2008), acetylation of histone
3 lysine 27 (H3K27Ac) (Creyghton et al., 2010; Rada-Iglesias
et al., 2011), and a high correlation with histone 3 lysine 4 mono-
methylation (H3K4me1) (Heintzman et al., 2007, 2009; Koch
et al., 2007). The presence of H3K4me1 and the absence of
H3K27Ac characterize poised enhancers (Creyghton et al.,
2010; Rada-Iglesias et al., 2011), which can be marked by
H3K27me3 in embryonic stem cells (ESCs; Rada-Iglesias
et al., 2011). Whether enhancers exist in a similar poised state
when paired with promoters carrying only repressive marks
(that is, H3K27me3 but not H3K4me3) has not been investigated.
The relevance of enhancers paired with inactive genes and their
effect on promoter epigenetic signatures is unclear.
In normal somatic cells, genes are typically expressed in
a tissue-specific manner or repressed by Polycomb-repressive
complex (PRC) and the associated H3K27me3 mark (Gal-Yam
et al., 2008). Interestingly, PRC targets are usually repressed,
yet poised for activation in ESCs, carrying the counteracting
active (H3K4me3) and repressive (H3K27me3) modifications
(Azuara et al., 2006; Bernstein et al., 2006). Therefore, repression
of gene activity by PRC is reversible. Furthermore, various
somatic cell types can be reprogrammed by overexpression of
some key factors with essential roles in determining cellular iden-
tity (Boukamp et al., 1992; Hollenberg et al., 1993; Lassar et al.,
1986; Weintraub et al., 1989). Reprogramming is an active area
of interest (Daley et al., 2011), and it is not yet known how key
transcriptional regulators initiate reprogramming, or if enhancers
contribute to such events.
To investigate the role of enhancers in detail, we use the
tissue-specific autoregulatory MYOD1 gene as a model for
understanding epigenetic interactions between enhancer/
promoter pairs. MYOD1 has a well-characterized enhancerCell 147, 1283–1294, December 9, 2011 ª2011 Elsevier Inc. 1283
located20 kb upstream of the TSS and contains aminimal core
region of 258 base pairs (bp) that is necessary for promoter
activity (Goldhamer et al., 1995). MYOD1 is expressed in
myoblasts but repressed in normal nonmuscle cells by PRC
and H3K27me3 (Gal-Yam et al., 2008). The presence of a well-
defined enhancer and a requirement for this transcription factor
in muscle lineage determination makeMYOD1 an optimal choice
for investigation of chromatin structures of an enhancer/
promoter pair in a variety of transcriptional contexts.
In this study, we used a high-resolution nucleosome occu-
pancy and methylome assay (NOMe-seq) to show that the
MYOD1 minimal enhancer exhibits a striking nucleosome-
depleted region (NDR) that is bordered by H2A.Z containing
nucleosomes marked with H3K4me1. This enhancer architec-
ture can be associated with both active and repressed promoter
states and is therefore more representative of a permissive state
rather than just active enhancers. We found that the PRC-occu-
pied promoter exhibits amultivalent epigenotype in somatic cells
and retains some regulatory flexibility, consistent with MYOD1
being in a transcriptionally competent state. In keeping with
this observation, the forced expression of exogenous Myod1
results in binding first at the enhancer, followed by chromatin
remodeling, causing the formation of a promoter NDR and
endogenous expression. Importantly, we also show that reprog-
ramming can be multidirectional. The binding of OCT4 to the
MYOD1 enhancer also precedes occupancy at the promoter,
which allows for establishment of a bivalent state that is charac-
teristic of stem cells. Thus, in two distinct contexts, the permis-
sive enhancer state orchestrates changes at the promoter
through binding of master regulatory factors. We extended our
analyses genome-wide and found that permissive enhancers
marked by H3K4me1 not only regulate transcriptionally active
promoters, but are also paired with PRC-repressed promoters.
We observed strikingly similar patterns in several somatic cell
types, indicating that this is not a cell-type specific event. Our
data suggest that the presence of counteracting epigenetic
states at enhancer/promoter pairs ensures the correct tissue
specific gene expression patterns of PRC targets, yet transcrip-
tional flexibility is retained. These findings provide insight into the
molecular events underlying reprogramming.
RESULTS
MYOD1, a Model for Studying Epigenetic Regulation
of an Enhancer/Promoter Pair
We performed detailed epigenetic analyses on the well-charac-
terized regulatory regions ofMYOD1 using two cell lines that con-
tained this gene in distinct transcriptional contexts. Quantitative
PCRconfirmed thatMYOD1 is expressed inahuman rhabdomyo-
sarcoma cell line (RD) but not normal human fibroblasts (LD419;
Figure 1A). Bisulfite sequencing revealed that the MYOD1
enhancer and promoter were not permanently silenced by DNA
methylation in fibroblasts (Figure 1A). ChIP assays confirmed
enrichment of H3K4me3 (Figure 1B) and phosphorylated RNA
polymerase II (Pol-IIP; Figure 1C) in RD cells, as well as Enhancer
of Zeste 2 (EZH2; Figure 1D) and H3K27me3 (Figure 1E) in LD419
cells. Thus, the selected cell lines were suitable for studying the
active (RD) and PRC-repressed (LD419) contexts ofMYOD1.1284 Cell 147, 1283–1294, December 9, 2011 ª2011 Elsevier Inc.TheMYOD1 Promoter Exhibits a Multivalent
Epigenotype When Repressed by PRC in Somatic Cells
H2A.Z is associated with key regulatory regions of transcription-
ally active and poised regulatory regions genome-wide (Barski
et al., 2007; Creyghton et al., 2008). Consistent with this,
H2A.Z was localized to the MYOD1 enhancer/promoter pair in
expressing cells (RD; Figure 1F). We found that H2A.Z remained
associated with the MYOD1 promoter even in the presence of
EZH2 and H3K27me3 in fibroblasts (LD419; Figure 1F) and
with the enhancer in these cells, though this distal region was
devoid of H3K27me3 and EZH2 (Figures 1D and 1E). H2A.Z
deposition at both proximal and distal gene regulatory regions
may therefore serve as onemechanism by which PRC-regulated
genes remain permissive.
Previous studies have shown that H3K4me1 is localized to
enhancers that act on transcriptionally active genes (Heintzman
et al., 2007; Koch et al., 2007; Visel et al., 2009). We examined
H3K4me1 profiles and, as anticipated, detected this modifica-
tion at theminimal enhancer inMYOD1 expressing cells (RD; Fig-
ure 1G). Unexpectedly, H3K4me1 was also detected at the
enhancer in fibroblasts (LD419; Figure 1G). H3K4me1, but not
the H3K4me3 mark characteristic of a bivalent promoter,
extended into the TSS ofMYOD1 in LD419 cells. Together, these
data suggest that the repressed promoter exhibits a multivalent
epigenetic signature marked by H2A.Z, H3K4me1 and
H3K27me3 in somatic cells. The presence of counteracting
histone modifications did not extend to the corresponding
enhancer, which was only enriched for marks associated with
transcriptional activity.
NDRs Characterize Permissive Enhancers
Nucleosomes are integral to epigenetic regulation, and mapping
their location is necessary to accurately view the epigenetic
landscape. Taking advantage of the fact that mammalian cells
are devoid of GpC methylation, we generate high-resolution
nucleosome positioning maps by incubating intact nuclei with
M.CviPI, a methyltransferase that recognizes GpC dinucleotides
not associated with nucleosomes or tightly bound transcription
factors (Kelly et al., 2010; Wolff et al., 2010; You et al., 2011).
This technique provides a digital readout of nucleosome occu-
pancy within individual DNA modules at CpG-rich and CpG-
poor regions, while retaining information regarding the endoge-
nous methylation states.
We examined nucleosome occupancy across the MYOD1
promoter and minimal enhancer in active and repressed states
(Figure 2). A prominent NDR was detected in 80% of enhancer
modules in cells expressing MYOD1 (RD; Figure 2A, left panel),
overlapping exactly with the minimal enhancer and missing at
least one nucleosome. Similar to the enhancer, we detected an
NDR in approximately 70% of promoter modules in these cells
(Figure 2A, right panel). Further, we found a highly positioned +1
nucleosome in 80% of promoter modules when an additional
75 bp region downstream of the TSS was included in our anal-
yses (data not shown). Together, these data show using
a high-resolution, single-molecule approach that enhancers
have open configurations, similar to promoters of active genes.
To determine whether NDRs were characteristic of enhancers
regulating PRC- and H3K27me3-repressed promoters (Figures
Figure 1. MYOD1 Exhibits a Multivalent Epigeno-
type When Repressed by PRC
(A) RNAwas isolated, reverse transcribed and analyzed by
qPCR using primers detecting MYOD1. Data are
expressed as copies of MYOD1 relative to GAPDH
expression (green bars). Average DNA methylation (%)
was determined by bisulfite sequencing and is expressed
as the average of 3 CpG dinucleotides across the
enhancer (black bars) and 33 CpG dinucleotides across
the promoter (hatched bars).
(B–G) ChIP assays were performed with antibodies
detecting (B) H3K4me3, (C) RNA PolII-P, (D) EZH2, (E)
H3K27me3, (F) H2A.Z, and (G) H3K4me1 on chromatin
from RD (green bars) and LD419 (red bars) cells.
Data are presented as percent total input. Bars, mean ±
SEM of three biological experiments.1D and 1E), we examined nucleosome occupancy at theMYOD1
enhancer in fibroblasts (LD419 cells). We found a striking deple-
tion of at least one nucleosome in approximately 40% of
enhancer modules in LD419 cells, remarkably similar to actively
expressing RD cells (compare Figures 2A and 2B, left panels).
The presence of an NDR (Figure 2), and H2A.Z and H3K4me1
enrichment (Figures 1F and 1G), highlights the epigenetic
similarities between the MYOD1 enhancer in two distinct tran-
scriptional contexts. Unlike the enhancer, however, every
promoter module was occupied by nucleosomes in LD419 cells
(Figure 2B, right panel). Nucleosomes located immediately
upstream of the TSS likely contribute to MYOD1 repression in
somatic cells. These data show that although promoters
repressed by PRC are occupied by nucleosomes, the corre-
sponding enhancermaintains an unexpected open configurationCell 147, 1283–1similar to enhancers of transcriptionally active
genes. Thus, specific histone modifications
and transcription factors, at least that have
been mapped to the enhancer in this study, do
not predict the activity of the promoter, suggest-
ing that the MYOD1 enhancer may exist in
a permissive state in fibroblasts and retain the
potential for gene activation in response to the
appropriate signals.
Transcriptional Competence
Is Determined by the Epigenetic
State of the Enhancer
To determine whether the enhancer NDR under-
lies the permissive nature of PRC-repressed
genes and facilitates reprogramming of endog-
enous MYOD1, we transfected LD419 cells
with a plasmid expressing TAP-tagged mouse
Myod1 and examined the Myod1 binding
kinetics using an anti-TAP antibody. At 6 hr,
Myod1 binding was not detected at either the
MYOD1 enhancer or promoter (Figure 3A).
Maximal association of Myod1 at the enhancer
occurred by 24 hr, at which time binding was
not observed at the MYOD1 promoter (Fig-
ure 3B). These data are consistent with the pres-ence of an NDR only at the enhancer (Figure 2), which would
physically allow for Myod1 binding. By 48 hr, Myod1 not only
associates with the enhancer but is also detected at the TSS
of MYOD1 in fibroblasts (Figure 3C), suggesting that the
promoter had been remodeled and an NDR generated, allowing
Myod1 to bind.
In support of this, we detected a newly formed NDR in 34%
of individual MYOD1 promoter modules in fibroblasts at 48 hr
posttransfection (LD419; Figure 3D, right panel). Interestingly,
the proportion of enhancer modules exhibiting an NDR
increased only marginally (<10%; Figure 3D, left panel) relative
to untransfected cells (compare to Figure 2B, left panel). Despite
Myod1 binding to its own regulatory regions (Figures 3B and 3C)
and equal transfection (Figure S1A available online), endogenous
MYOD1 mRNA expression was only detected when transfected294, December 9, 2011 ª2011 Elsevier Inc. 1285
Figure 2. Nucleosome-Depleted Regions Characterize Permissive
Enhancers
Nuclei were extracted from (A) RD and (B) LD419 cells and treated withM.CviPI
GpC methyltransferase and subjected to bisulfite conversion and cloning.
Horizontal lines represent individualMYOD1enhancers (left) orpromoters (right).
Circles represent GpC dinucleotides (white, unmethylated and inaccessible to
M.CviPI; teal, methylated and accessible to M.CviPI). Pink bars areR146 bp,
representing sites associatedwith nucleosomes.Regions accessible toM.CviPI
(teal) indicate NDRs. Arrow denotes the TSS. Diagram is drawn to scale.cells were cultured in medium conditioned by RD cells (Fig-
ure S1B), suggesting a requirement for an additional factor that
positively induces MYOD1 expression. Identifying specific
factors is beyond the scope of this study, though possible candi-
dates include thyroid hormones or insulin-like growth factors
(Carnac et al., 1992; Pinset et al., 1988). Conditioned medium
results in additional promoter chromatin remodeling in trans-
fected cells, an increase in DNA modules with an NDR (60%;
Figure S1C) and acquisition of active epigenetic marks (Figures
S1D–S1F).
An Enhancer NDR Enables Transcription Factor Binding
and Promoter Chromatin Remodeling
To investigate the requirement of the enhancer NDR in reprog-
ramming events, we took advantage of the RKO colorectal cell
line, which also does not express MYOD1. In contrast to fibro-
blasts, the enhancer and promoter of MYOD1 are occupied by
nucleosomes in RKO cells (NOME-seq, data not shown), allow-
ing us to determine the mechanistic significance of the permis-
sive chromatin state. Thus, we transfected RKO cells with
Myod1-TAP and compared Myod1 binding, as previously. We
chose to examine Myod1 occupancy in these cells at 48 hr post-
transfection, which was at the time point when we saw maximal1286 Cell 147, 1283–1294, December 9, 2011 ª2011 Elsevier Inc.Myod1 binding at the MYOD1 enhancer/promoter pair in fibro-
blasts (Figure 3C). Similar to our kinetic study, we see Myod1
associating with the enhancer and promoter of MYOD1 in fibro-
blasts (Figure 3E, black bars). In striking contrast, the MYOD1
enhancer and promoter regions in RKO cells are devoid of
Myod1 binding at 48 hr posttransfection (Figure 3E, gray bars).
Thus, Myod1 does not physically bind to the enhancer nor do
we see subsequent binding or chromatin remodeling events at
the MYOD1 promoter in these cells (Figure 3F).
MYOD1 Gains a Bivalent State after OCT4 Initiates
Reprogramming through the Enhancer
Induced pluripotent stem cells (iPSCs) can be generated from
somatic cells by forced expression of key transcription factors,
such as OCT4 (Maherali et al., 2007; Takahashi et al., 2007;
Takahashi and Yamanaka, 2006). OCT4 association with PRC
targets in ESCs correlates with gene inactivity and the presence
of a bivalent epigenetic promoter signature (Bernstein et al.,
2006). A bivalent signature (containing both H3K4me3 and
H3K27me3) in ESCs allows developmentally important genes
to be poised for activation while remaining transcriptionally inac-
tive. Interestingly, the MYOD1 enhancer contains an OCT4
consensus sequence. Critically, no such sequence exists at
the promoter, providing a unique system to investigate changes
in the enhancer/promoter epigenetic signature. By forcing
expression of OCT4 in fibroblasts to initiate processes involved
in iPSC generation, we sought to investigate the kinetic events
associated with establishing a bivalent state. We transfected
LD419 cells with a plasmid expressing OCT4 and examined
the binding kinetics using an anti-OCT4 antibody. Inmock-trans-
fected cells (0 hr), only a minimal level of OCT4 binding was
detected at both theMYOD1 enhancer and promoter (Figure 4A).
OCT4 occupancy at the enhancer occurred by 24 hr, at which
time binding was not enriched at the MYOD1 promoter (Fig-
ure 4A). These data are highly similar to those observed for
Myod1 (Figure 3B) and consistent with the presence of an NDR
only at the enhancer (Figure 2). By 72 hr, we then detected
OCT4 at the MYOD1 promoter (Figure 4A). Interestingly, 72 hr
after OCT4 overexpression, the H3K4me1 modification at the
MYOD1 promoter was replaced by H3K4me3 while maintaining
H3K27me3 (Figures 4B–4D), indicating that the MYOD1
promoter reverted to a bivalent chromatin signature typical of
developmentally important genes in iPSCs and ESCs. There is
a lower level of H3K27me3 at both the promoter and enhancer
in this state (Figure 4C, 72 hr), consistent with previous reports
that PRC activity is inhibited by the presence of H3K4me3
(Schmitges et al., 2011) and perhaps H3K4me1. We also
analyzed the promoter and putative enhancer of GRP78,
a constitutively expressed gene, to control for pull-down effi-
ciency (Figure S2A). The enhancer was enriched for H3K4me1
in the basal state (0 hr) and was not altered upon OCT4 overex-
pression (72 hr). As expected, the promoter carried the
H3K4me3 modification but was devoid of the repressive
H3K27me3 mark even after OCT4 expression. Importantly,
only aminimal level of OCT4was present at theGRP78 enhancer
and promoter after 72 hr (Figure S2A), demonstrating that the
presence of OCT4 is not generalized to all enhancers and
promoters. Investigation of nucleosome occupancies showed
Figure 3. The Enhancer NDR Underlies MYOD1 Transcriptional Competence
(A–C) ChIP assays were performed with an anti-TAP antibody on chromatin from LD419 cells transfected with Myod1-TAP for (A) 6 hr, (B) 24 hr, or (C) 48 hr. Data
are presented as percent total input.
(D) Nuclei were extracted from LD419 cells transfected with Myod1-TAP for 48 hr and then treated with M.CviPI as described previously (see Figure 2).
(E) ChIP assays were performed with an anti-TAP antibody on chromatin from LD419 (black bars) or RKO (gray bars) cells transfected with Myod1-TAP for 48 hr.
The data are presented as percent total input.
(F) Nuclei were extracted from RKO cells transfected with Myod1-TAP for 48 hr and then treated with M.CviPI as described for LD419 cells.
See also Figure S1. Bars, mean ± SEM of three biological experiments.that the bivalent state remains permissive in that the enhancer
still exhibits an NDR, while the promoter is nucleosome occupied
(Figure S2B). Together, these data offer insight into themolecular
events that establish bivalent epigenetic signatures and provides
additional evidence that reprogramming is likely initiated through
nucleosome-depleted enhancer regions.
Enhancer/Promoter Crosstalk Underlies
Reprogramming Events
To understand the mechanisms underlying reprogramming of
MYOD1, we next examined the involvement of proteincomplexes in facilitating enhancer/promoter interactions. To
definitively demonstrate enhancer/promoter looping, a chromo-
some conformation capture assay (3C) can be performed.
However, 3C can be unreliable when assessing genomic regions
that are as close as 20 kb apart (Dekker, 2006; Dekker et al.,
2002; Miele and Dekker, 2009), as is the case for the MYOD1
enhancer and promoter. Nonetheless, the presence of the cohe-
sin protein complex is consistent with DNA looping and
enhancer/promoter interactions (Kagey et al., 2010). Thus, we
measured the presence of the cohesin complex at the MYOD1
enhancer and promoter using an antibody raised against a highlyCell 147, 1283–1294, December 9, 2011 ª2011 Elsevier Inc. 1287
Figure 4. MYOD1 Gains a Bivalent State after
OCT4 Initiates Reprogramming through the
Enhancer
ChIP assays were performed with (A) anti-OCT4 (black),
(B) anti-H3K4me3 (green), (C) anti-H3K27me3 (red), and
(D) anti-H3K4me1 (gray) antibodies on chromatin from
LD419 cells transfected with OCT4 for 0 (mock), 24, or
72 hr (left, center, and right panels, respectively). Data are
presented as percent total input. Bars, mean ± SEM of
three biological experiments. See also Figure S2.conserved subunit of the complex, RAD21 (Schmidt et al.,
2010). We observed RAD21 binding at the enhancer and
promoter regions in expressing cells (RD, black bars; Fig-
ure S3A). An shRNA-targeted knockdown of RAD21 caused
a reduction in RAD21 protein (Figure S3B) and mRNA levels
(Figure S3C, black bars). Importantly, this resulted in reduced
MYOD1 expression in RD cells (Figure S3C, green bars), again
consistent with the requirement of this complex for DNA loop-
ing. We next investigated the necessity for RAD21 in epigenetic
reprogramming of MYOD1 in normal human fibroblasts, where
MYOD1 is repressed. In LD419 cells a residual amount of
RAD21 was bound to the MYOD1 promoter, while the enhancer
and inter-regulatory regions were devoid of RAD21 (black bars;
Figure 5). Following exogenous Myod1 expression, a small
amount of RAD21 was detected at the enhancer at 24 hr post-
transfection, but promoter occupancy did not change (white
bars, Figure 5), whereas at 48 hr, RAD21 occupancy increases
at both the enhancer and promoter (red bars, Figure 5). The
presence of cohesin at both the enhancer and promoter is
consistent with enhancer/promoter interaction (Kagey
et al., 2010).
Taken together, our data demonstrate that transcription factor
binding to the enhancer precedes binding to the promoter,1288 Cell 147, 1283–1294, December 9, 2011 ª2011 Elsevier Inc.providing evidence that the enhancer NDR
underlies a permissive state and directs
MYOD1 promoter chromatin remodeling in
response to the appropriate signals (Figures
3D and S1B), and expression in the presence
of the correct factors (Figure S1A). The ability
of enhancers to drive changes at promoters
provides a potential mechanism for
reprogramming.
H3K4me1 Marks Enhancers of
Transcriptionally Active, as Well as
PRC-Repressed, Genes
Epigenome-wide studies have identified corre-
lations between enhancers marked by
H3K4me1 and promoter transcriptional activity
(Heintzman et al., 2007; Koch et al., 2007; Visel
et al., 2009). However, these studies have not
explicitly considered the epigenetic signatures
of enhancers paired with inactive promoters.
We sought to extend our investigation of
MYOD1 and specifically asked whether
enhancers marked by H3K4me1 could also beassociated with PRC-repressed promoters genome-wide, as
indicated by the presence of the H3K27me3 mark.
Previous reports indicate that enhancers located within 10
kb of TSS are statistically linked to promoter activity and that
those located upstream of the TSS are more likely to influence
transcription (MacIsaac et al., 2010). Although enhancers may
be located several hundreds of kb away (Atchison and Perry,
1988), additional evidence suggests that enhancers are likely
to act on the closest promoter in many situations (Xi et al.,
2007). Therefore, we focused our analyses on those enhancers
located in a 10 kb window upstream of the TSS (from 2
to 12 kb) to encompass the same approximate region identi-
fied by MacIsaac et al. (2010), while eliminating the effect of
epigenetic marks at adjacent promoters (<2 kb). We probed
publicly available ENCODE data sets using the epigenome-
wide profiles of genomic regions containing either H3K4me1,
H3K4me3 or H3K27me3 of the following human cell lines:
ESCs (H1), B lymphocytes (GM12878), human mammary epi-
thelial cells (HMEC), normal human epidermal keratino-
cytes (NHEK) and normal human lung fibroblasts (NHLF) (Kellis
et al., 2011).
We asked whether TSS with promoters marked by either
H3K4me3 or H3K27me3 had at least one putative enhancer
Figure 6. H3K4me1 Marks Enhancers of Transcriptionally Active, as
Well as PRC-Repressed, Genes
For each cell line, genes with the histone modifications (A) H3K4me3 or (B)
H3K27me3 at promoters (defined as ± 500 bases around the TSS) were
identified, and the percentage of those promoters with putative H3K4me1
enhancer regions (defined to be the2 to12 kb window located upstream of
the TSS) were calculated (green/red bars, left y axes). Similarly, DNase
hypersensitivity (black bars, right y axes) was examined and are expressed as
a percentage of those promoters (A) H3K4me3 or (B) H3K27me3 with
H3K4me1 marked enhancers that exhibit DNase hypersensitivity (DHS). kb,
kilobase; arrow, TSS. See also Figures S4 and S5.
Figure 5. Enhancer/Promoter Interactions Underlie Reprogramming
Events
ChIP assays were performed with an anti-RAD21 antibody on untransfected
LD419 cells (0 hr, black bars) and LD419 cells transfected with Myod1-TAP for
24 (white bars) or 48 hr (red bars), as indicated. The data are presented as
percent total input. Bars, mean ± SEM of three biological experiments. See
also Figure S3.marked by H3K4me1 within a 10 kb window upstream of the
TSS (2 to 12 kb; Figures 6A and 6B). As expected, >70%
of active promoters with H3K4me3-enriched promoters are
paired with enhancers enriched for H3K4me1 across cell types,
including ESCs (2 to 12 kb; left y axis, Figure 6A). The
majority of these enhancers are DNase hypersensitive (i.e.,
likely depleted of nucleosomes) in normal somatic cells
(56%–64%; right y axis, Figure 6A). We noted that the propor-
tion of DNase hypersensitive enhancers, which are presumably
nucleosome depleted, was lower in ESCs (49%) compared to
somatic cells. H3K27me3 promoters could also have at least
one putative enhancer enriched for H3K4me1 located in this
10 kb window (Figure 6B). The percentage of H3K27me3
marked promoters with putative enhancers varied between
somatic cell types (27%–57%; Figure 6B, left y axis) and was
substantially higher in ESCs (87%; Figure 6B, left y axis).
Many enhancers paired with H3K27me3 marked promoters
are sensitive to DNase (48%–62%, Figure 6B, right y axis),
consistent with nucleosome depletion and as we found with
MYOD1 in fibroblasts (Figure 2B). Together, these data suggest
that H3K4me1 marked enhancers vary in their DNase hyper-
sensitivity and are associated with both active and PRC-
repressed promoters.
To extend our findings beyond MYOD1, we examined two
additional PRC target genes with validated enhancers PAX6
(Heintzman et al., 2009) and NODAL (Rada-Iglesias et al.,
2011) within several ENCODE cell lines. The promoters of
PAX6 and NODAL were enriched for H3K27me3, whereas their
enhancers exhibited H3K4me1 in the cell types examined
(Figures S4A and S5A). Examining the chromatin configura-
tions of PAX6 and NODAL in more detail (Figures S4B and
S5B), we showed that PAX6 and NODAL were devoid of
H3K4me3 and Pol-IIP, yet enriched for EZH2, H3K27me3,H2A.Z, and H3K4me1, consistent with expression (data not
shown) in fibroblasts. These data confirm that the generality
of our findings can be applied to additional genes and cell
types.
Together, H3K4me1 is not a defining mark of ‘‘active’’
enhancers alone. Indeed, our data suggest that PRC-repressed
promoters can potentially be activated (Figures 3 and 4) and
therefore, the enrichment of this histone modification more
accurately represents ‘‘permissive’’ enhancers that coexist
with at least two distinct promoter contexts.Cell 147, 1283–1294, December 9, 2011 ª2011 Elsevier Inc. 1289
DISCUSSION
The ability of enhancers to regulate genes in cis and trans has
made correlating enhancers with their promoters challenging.
Our data emphasize the importance of understanding how
enhancer/promoter pairs work together to obtain an accurate
view of epigenetic gene regulation. Interestingly, we found that
PRC-repressed promoters have permissive enhancers in
somatic cells. Conventionally, ‘‘active’’ enhancers (H3K4me1)
are paired with transcriptionally active promoters (H3K4me3),
yet we show that they can also potentially regulate multivalent
promoters (H3K27me3/H2A.Z). Therefore, the term ‘‘active’’ to
describe enhancers characterized by H2A.Z incorporation,
H3K4me1 enrichment, and nucleosome depletion may be
misleading, and thus we propose the use of ‘‘permissive’’ to
describe such enhancers. In this way, ‘‘permissive’’ describes
the epigenetic signature, and also refers to the biological func-
tions of these regulatory regions. Although enhancers can regu-
late promoters at greater distances or on different chromo-
somes, Xi et al., (2007) showed that enhancers are likely to act
on the closest promoter in many situations. We found that
27%–57% of PRC-repressed promoters have putative en-
hancers marked by H3K4me1 located 2 to 12 kb upstream
of their TSS and at least 48% of them are DNase hypersensitive.
Therefore, we suggest that the majority of enhancers found to be
nonfunctional in verification assays (22%; Heintzman et al.,
2009) might actually represent permissive enhancers that can
potentially regulate a PRC occupied promoter.
It is formally possible that the permissive enhancers identified
in our epigenome-wide analyses may be activating alternate
gene promoters. Thus, we focused on human MYOD1, whose
distal enhancer is extremely well characterized and to our knowl-
edge has not been associated with any other gene. This
enhancer is critical for MYOD1 activation during development
and lineage commitment (Faerman et al., 1995; Goldhamer
et al., 1995; Kablar et al., 1999). An additional enhancer located
4.8 kb upstream of the TSS also contributes toMYOD1 expres-
sion, yet this is restricted to a subset of cells that are already
committed (Asakura et al., 1995; Kablar et al., 1997; Tapscott
et al., 1992). The distal enhancer/promoter crosstalk we
describe here points to a mechanism for this previous work.
Using MYOD1, we show that an NDR at the minimal enhancer
region allows reprogramming to be initiated, which occurs in
response to signals such as the forced expression of Myod1 in
fibroblasts. The nucleosome footprint at the minimal enhancer
was only slightly altered in response to Myod1 expression, sug-
gesting that additional chromatin remodeling of enhancer
modules is not required for epigenetic crosstalk between the
enhancer/promoter pair. In contrast, the endogenous MYOD1
promoter is dramatically remodeled, and an NDR is formed in
response to Myod1 expression. It is unclear how the enhancer
NDR is established and maintained in the absence of an active
promoter. Nucleosome assembly may be inhibited by the
binding of an unidentified transcription factor(s) that establishes
and maintains the NDR (e.g., You et al., 2011). These events did
not occur when a nucleosome occupies the MYOD1 enhancer
and impedes transcription factor binding. Thus, it is possible
that an unidentified factor associates with theMYOD1 enhancer1290 Cell 147, 1283–1294, December 9, 2011 ª2011 Elsevier Inc.in LD419 but not in RKO cells, explaining the difference in chro-
matin architecture and the inability of these cells to be reprog-
rammed. Nonetheless, our data highlight the importance of the
underlying chromatin state in reprogramming events.
The MYOD1 enhancer also contains an OCT4 consensus
sequence, which is not present at the promoter, providing an
unequivocal system for investigating changes in the epigenetic
signature. Thus, any epigenetic changes that are detected, and
the appearance of OCT4 at the promoter (even though there is
no binding site), are most likely explained by enhancer/promoter
interactions. By forcing OCT4 expression in fibroblasts to initiate
processes involved in iPSC generation, we show the kinetic
events associatedwith establishing a bivalent state. As a bivalent
state is generated, H3K27me3 is reduced at the enhancer.
Whether H3K27me3 is replaced by H3K27Ac is yet to be deter-
mined. The replacement of H3K4me1 by H3K4me3 at the
promoter, while maintaining H3K27me3, indicates that the
MYOD1 promoter reverts to a bivalent chromatin signature in
response to forced OCT4 expression. OCT4 may play a direct
role in establishing bivalency at MYOD1, although it is also
possible that OCT4 expression causes global changes that indi-
rectly lead to this promoter state. A more detailed kinetic study
might distinguish between these possibilities.
The OCT4 experiments together with Myod1 show that re-
programming is multidirectional and is ultimately determined
by the master transcription factor. Regardless, reprogramming
is driven through the nucleosome-depleted enhancer, repre-
senting a permissive state and supporting a model that tran-
scription factor binding first to the enhancer is responsible for
epigenetic changes at the promoter (Figure 7).
Our study demonstrates that theMYOD1 promoter is multiva-
lent, carrying epigenetic marks correlated with activation
(H3K4me1 and H2A.Z) as well as repression (H3K27me3 and
EZH2) in somatic cells. Similar multivalency has been described
whereby H2A.Z localizes to H3K27me3-enriched genomic
regions in ESCs (Creyghton et al., 2008). This is comparable to
the bivalent signature described in ESCs (H3K4me3 and
H3K27me3) (Azuara et al., 2006; Bernstein et al., 2006), which
likely keeps genes poised for induction. Themultivalent epigeno-
type may be generated from a bivalent state in ESCs or gener-
ated during lineage commitment. The maintenance of multiva-
lency and the ability to acquire these epigenetic modifications
in the correct order may explain why some somatic cells are
more suitable for generating iPSCs (Maherali et al., 2007; Taka-
hashi et al., 2007; Takahashi and Yamanaka, 2006) and why
some are resistant to reprogramming (Boukamp et al., 1992).
The specific roles of H2A.Z and H3K4me1 in maintaining
a permissive environment are unclear. H2A.Z is localized to
the MYOD1 enhancer and promoter in both RD cells and
LD419 cells, consistent with its localization to active and poised
regulatory regions. The incorporation of H2A.Z may lead to
altered nucleosome stability in certain contexts (Jin et al.,
2009), providing a reason for H2A.Z marked nucleosomes at
the PRC occupied promoter. The role of H3K4me1 is less clear,
and the fact that it marks both the promoter and enhancer of
PRC-repressed genes is interesting. Moreover, H3K4me1 is
resolved to H3K4me3 at the promoter in expressing cells.
The resolution of H3K4me1 to a di- or trimethyl group is not
Figure 7. Polycomb-Repressed Promoters Maintain Regulatory Flexibility through Epigenetic Crosstalk with Their Permissive Enhancers
A model shows a permissive enhancer is highly comparable to the active enhancer, exemplified by the NDR and H3K4me1 despite the presence of promoter
nucleosomes carrying H3K27me3. Reprogramming can be orchestrated from this permissive state by master transcription factors such as Myod1 or OCT4 that
access their target through the enhancer. Myod1 overexpression activates a self-regulatory mechanism by binding first to its own enhancer, resulting in
recruitment of RAD21 (the cohesin complex), consistent with enhancer/promoter interactions. Promoter changes follow, such as nucleosome eviction and
transcription factor occupancy near the TSS. Enhancer-mediated reprogramming is also observed after overexpression of OCT4, resulting in the generation of
a bivalent promoter state. Together, these data demonstrate that reprogramming can be forced in multiple directions yet is initiated from the enhancer. NDR,
nucleosome-depleted region; small white circle, unmethylated CpG site; small black circle, methylated CpG site; large circle, nucleosome; 4me1 (dark green),
H3K4me1; 4me3 (light green), H3K4me3; 27me3 (red), H3K27me3; AcH3, acetylated H3; X, inactive TSS.observed at the enhancer, irrespective of the transcriptional
state, suggesting that it may have independent roles at distinct
gene regulatory regions. It is possible that the H3K4me1 mark
acts as a foundation for the addition of methyl groups, resulting
in H3K4me2 and H3K4me3 and perhaps priming the promoterfor activation. Such dynamic changes have been reported in
studies of H3K4me kinetics in developing embryos (Lepikhov
and Walter, 2004). Finally, the presence of H3K4me1 may
simply prevent spurious epigenetic activity. It is feasible that
enrichment of H3K4me1 interferes with epigenetic silencingCell 147, 1283–1294, December 9, 2011 ª2011 Elsevier Inc. 1291
mechanisms, much like H2A.Z is mutually exclusive with DNA
methylation.
Particular emphasis was placed on nucleosome occupancy
in our study, utilizing the high-resolution NOME-seq approach,
which provides direct evidence that nucleosomes contribute to
the repression of PRC target gene promoters in somatic cells,
as well as the finding that an NDR is present at the enhancer
in opposing transcriptional states. Notably, these data are pre-
sented in the context of an enhancer/promoter pair, which we
show is necessary to draw accurate conclusions regarding
the status of a gene. Our results also indicate that H3K4me1
marked enhancers contribute to the epigenetic regulation of
PRC target genes across the genome. Biologically, the pres-
ence of an NDR might enable the enhancer to respond to
activating signals, which triggers promoter chromatin remodel-
ing and causes a promoter NDR to form. This may explain
how transcription factors gain access to their targets and
how repressive chromatin states impede reprogramming
events. In fact, our data demonstrate that the enhancer of
PRC target genes may allow these loci to remain permissive
in somatic cells, retaining epigenetic plasticity and initiating
reprogramming.EXPERIMENTAL PROCEDURES
Cell Culture
The RD and colorectal (RKO) cell lines were obtained from the American Type
Culture Collection (ATCC) and cultured under recommended conditions. A
normal human fibroblast cell line (LD419) was generated in our laboratory
and cultured in McCoy’s 5A medium supplemented with 20% FBS,
100 U/ml penicillin and 100 mg/ml streptomycin at 37C and 5% CO2.RNA Isolation and Quantitative PCR Analysis
RNA was isolated using Trizol reagent, digested with DNase I, and reverse
transcribed (iScript, BioRad). cDNA was amplified using the CFX96 Real-
time PCR detection system (BioRad) and SYBR Fast qPCR Mix (Kapa Bio-
systems) under the following conditions: 95C for 3 min, followed by 45 cycles
of 95C for 3 s then 60C for 30 s. A melt curve analysis was performed (60C
–95C, rising by 1C every 5 s). Oligonucleotides are listed in Table S1. Anal-
yses were conducted in parallel using human GAPDH for normalization. A
standard curve was generated for each primer set to correlate threshold (Ct)
values to copy number.
Nucleosome Occupancy and Methylome Sequencing
Nuclei were extracted as described previously (Schreiber et al., 1989).
Briefly, cells were trypsinized and centrifuged for 3 min at 500 3 g, then
washed in ice-cold PBS and resuspended in 1 ml ice-cold nuclei buffer
(10 mM Tris [pH 7.4], 10 mM NaCl, 3 mM MgCl2, 0.1 mM EDTA, and
0.5% NP-40, plus protease inhibitors) per 5 3 106 cells and incubated on
ice for 5 min. Nuclei were recovered by centrifugation at 900 3 g for
3 min and washed in nuclei wash buffer (10 mM Tris [pH 7.4], 10 mM
NaCl, 3 mM MgCl2, and 0.1 mM EDTA containing protease inhibitors).
Freshly prepared nuclei (2 3 105 cells) were resuspended in 13 M.CviPI
reaction buffer (NEB), then treated with 200 U of M.CviPI (NEB) in 15 ml
103 reaction buffer, 45 ml 1M sucrose, and 0.75 ml SAM in a volume of
150 ml. Reactions were quenched by the addition of an equal volume of
Stop Solution (20 nM Tris-HCl [pH 7.9], 600 mM NaCl, 1% SDS, 10 mM
EDTA, 400 mg/ml Proteinase K) and incubated at 55C overnight. DNA was
purified by phenol/chloroform extraction and ethanol precipitation. Bisulfite
conversion was performed using the Epitect Bisulfite Kit (QIAGEN). Mole-
cules were cloned using the Topo TA Kit (Invitrogen), both according to
the manufacturers’ instructions.1292 Cell 147, 1283–1294, December 9, 2011 ª2011 Elsevier Inc.Transfections
The Myod1-TAP and OCT4 plasmids were obtained from Addgene. Transfec-
tions were performed using Lipofectamine LTX and Plus Reagent (Invitrogen)
according to the manufacturers’ instructions. Mock transfections served as
negative controls. Transfections were performed in 10 cm tissue culture plates
using 12.5 mg of Myod1-TAP or OCT4 plasmid DNA. For conditioned medium
experiments, RD cells (23 106) were cultured for 24 hr in McCoy’s 5A supple-
mented with 20% FBS, without penicillin/streptomycin. Medium was sterile
filtered to remove debris and detached cells. Medium was added to LD419
cells 6 hr posttransfection and replaced at 24 hr. Cells were harvested as
required.Chromatin Immunoprecipitation
Chromatin immunoprecipitation (ChIP) assays were performed as previously
(Kelly et al., 2010). For assays using anti-H3K4me1, anti-TAP, and anti-
RAD21 antibodies, nuclei were purified after formaldehyde crosslinking, then
resuspended in SDS lysis buffer before sonication. Antibodies (10 mg) used
for ChIP experiments included histone H3 (#ab1791, Abcam), H2A.Z
(#ab4174, Abcam), H3K4me1 (#39298, Active Motif), H3K4me3 (#39160,
Active Motif), H3K27me3 (#07-360, Millipore), EZH2 (#39639, Active Motif),
RNA Polymerase II (phosphorylated) (#ab24758, Abcam), RNA Polymerase II
(#ab817, Abcam), TAP (#CAB1001, Open Biosystems), RAD21 (#ab992,
Abcam), and CD8 (#sc-32812, Santa Cruz). Quantitative PCR (qPCR) for
ChIP was performed as described for mRNA analyses. Oligonucleotides are
listed in Table S1. For each PCR, DNA standards were included for quantita-
tion. Samples were also immunoprecipitated with a nonspecific antibody
(CD8) to control for background enrichment. Immunoprecipitated DNA was
calculated as a percentage of input DNA.Epigenome-wide Analyses of Enhancer/Promoter Pairs
From the UCSC Genome Browser (Raney et al., 2011), we downloaded the
ENCODE epigenome-wide modification profiles of H4K3me1, H4K3me3,
and H3K27me3 for five cell lines: ESCs (ES), B lymphocytes (GM12878),
human mammary epithelial cells (HMEC), NHEK, and NHLF (Kellis et al.,
2011). For the same cell lines, we also downloaded genome-scale mapping
of DNase I sensitivity data (Stamatoyannopoulos et al., 2006). We used the
UCSC KnownGene database to define the transcriptional start site (TSS).
For 66,803 KnownGenes, we defined putative promoter regions to be ±500
bases around the TSS, and putative enhancer regions to be -(X + 10 kb)
or –(X + 1 kb) upstream of the TSS (where X = 2 kb, 3 kb, ., 10 kb). For
each cell line, we counted the number of KnownGenes with either H4K3me3
or H3K27me3 at the promoter, and the percentage of those with H4K3me1
at the enhancer, respectively. We also determined the proportion of
H3K4me1 marked enhancers that exhibit DNase hypersensitivity.SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, five
figures, and one table and can be found with this article online at doi:10.
1016/j.cell.2011.10.040.ACKNOWLEDGMENTS
We thank Dr. Adele Murrell for helpful advice and suggestions. We thank Dr. C.
Andreu-Vieyra and Fides Lay for critical review of the manuscript. Funding for
this work to P.A.J. was provided by NIH R37 CA-082422 and G.L. by R01
CA-124518. X.J.Z. was supported by an NSF Career Award 0747475. T.K.K.
was funded by NIH 5T32 CA-009320-27 and an ARCS fellowship.
Received: October 8, 2010
Revised: August 5, 2011
Accepted: October 6, 2011
Published: December 8, 2011
REFERENCES
Asakura, A., Lyons, G.E., and Tapscott, S.J. (1995). The regulation of MyoD
gene expression: conserved elements mediate expression in embryonic axial
muscle. Dev. Biol. 171, 386–398.
Atchison, M.L., and Perry, R.P. (1988). Complementation between two cell
lines lacking kappa enhancer activity: implications for the developmental
control of immunoglobulin transcription. EMBO J. 7, 4213–4220.
Azuara, V., Perry, P., Sauer, S., Spivakov, M., Jørgensen, H.F., John, R.M.,
Gouti, M., Casanova, M., Warnes, G., Merkenschlager, M., and Fisher, A.G.
(2006). Chromatin signatures of pluripotent cell lines. Nat. Cell Biol. 8, 532–538.
Barski, A., Cuddapah, S., Cui, K., Roh, T.Y., Schones, D.E., Wang, Z., Wei, G.,
Chepelev, I., and Zhao, K. (2007). High-resolution profiling of histone methyl-
ations in the human genome. Cell 129, 823–837.
Bernstein, B.E., Mikkelsen, T.S., Xie, X., Kamal, M., Huebert, D.J., Cuff, J., Fry,
B., Meissner, A., Wernig, M., Plath, K., et al. (2006). A bivalent chromatin struc-
turemarkskeydevelopmental genes inembryonic stemcells.Cell125, 315–326.
Boukamp, P., Chen, J., Gonzales, F., Jones, P.A., and Fusenig, N.E. (1992).
Progressive stages of ‘‘transdifferentiation’’ from epidermal to mesenchymal
phenotype induced byMyoD1 transfection, 5-aza-20-deoxycytidine treatment,
and selection for reduced cell attachment in the human keratinocyte line
HaCaT. J. Cell Biol. 116, 1257–1271.
Carnac, G., Albagli-Curiel, O., Vandromme, M., Pinset, C., Montarras, D., Lau-
det, V., and Bonnieu, A. (1992). 3,5,30-Triiodothyronine positively regulates
both MyoD1 gene transcription and terminal differentiation in C2 myoblasts.
Mol. Endocrinol. 6, 1185–1194.
Creyghton, M.P., Markoulaki, S., Levine, S.S., Hanna, J., Lodato, M.A., Sha,
K., Young, R.A., Jaenisch, R., and Boyer, L.A. (2008). H2AZ is enriched at poly-
comb complex target genes in ES cells and is necessary for lineage commit-
ment. Cell 135, 649–661.
Creyghton, M.P., Cheng, A.W., Welstead, G.G., Kooistra, T., Carey, B.W.,
Steine, E.J., Hanna, J., Lodato, M.A., Frampton, G.M., Sharp, P.A., et al.
(2010). Histone H3K27ac separates active from poised enhancers and
predicts developmental state. Proc. Natl. Acad. Sci. USA 107, 21931–
21936.
Daley, G., Surani, A., Tanaka, E., and Plath, K. (2011). Reprogramming: What’s
Unknown? Cell 145, 811–812.
Dekker, J. (2006). The three ‘C’ s of chromosome conformation capture:
controls, controls, controls. Nat. Methods 3, 17–21.
Dekker, J., Rippe, K., Dekker, M., and Kleckner, N. (2002). Capturing chromo-
some conformation. Science 295, 1306–1311.
Faerman, A., Goldhamer, D.J., Puzis, R., Emerson, C.P., Jr., and Shani, M.
(1995). The distal human myoD enhancer sequences direct unique muscle-
specific patterns of lacZ expression during mouse development. Dev. Biol.
171, 27–38.
Gal-Yam, E.N., Egger, G., Iniguez, L., Holster, H., Einarsson, S., Zhang, X., Lin,
J.C., Liang, G., Jones, P.A., and Tanay, A. (2008). Frequent switching of Poly-
comb repressivemarks and DNA hypermethylation in the PC3 prostate cancer
cell line. Proc. Natl. Acad. Sci. USA 105, 12979–12984.
Goldhamer, D.J., Brunk, B.P., Faerman, A., King, A., Shani, M., and Emerson,
C.P., Jr. (1995). Embryonic activation of themyoD gene is regulated by a highly
conserved distal control element. Development 121, 637–649.
Heintzman, N.D., Stuart, R.K., Hon, G., Fu, Y., Ching, C.W., Hawkins, R.D.,
Barrera, L.O., Van Calcar, S., Qu, C., Ching, K.A., et al. (2007). Distinct and
predictive chromatin signatures of transcriptional promoters and enhancers
in the human genome. Nat. Genet. 39, 311–318.
Heintzman, N.D., Hon, G.C., Hawkins, R.D., Kheradpour, P., Stark, A., Harp,
L.F., Ye, Z., Lee, L.K., Stuart, R.K., Ching, C.W., et al. (2009). Histone modifi-
cations at human enhancers reflect global cell-type-specific gene expression.
Nature 459, 108–112.
Hinshelwood, R.A., Melki, J.R., Huschtscha, L.I., Paul, C., Song, J.Z., Stir-
zaker, C., Reddel, R.R., and Clark, S.J. (2009). Aberrant de novo methylation
of the p16INK4A CpG island is initiated post gene silencing in associationwith chromatin remodelling and mimics nucleosome positioning. Hum. Mol.
Genet. 18, 3098–3109.
Hollenberg, S.M., Cheng, P.F., and Weintraub, H. (1993). Use of a conditional
MyoD transcription factor in studies of MyoD trans-activation and muscle
determination. Proc. Natl. Acad. Sci. USA 90, 8028–8032.
Jin, C., Zang, C.,Wei, G., Cui, K., Peng,W., Zhao, K., and Felsenfeld, G. (2009).
H3.3/H2A.Z double variant-containing nucleosomes mark ‘nucleosome-free
regions’ of active promoters and other regulatory regions. Nat. Genet. 41,
941–945.
Kablar, B., Krastel, K., Ying, C., Asakura, A., Tapscott, S.J., and Rudnicki, M.A.
(1997). MyoD and Myf-5 differentially regulate the development of limb versus
trunk skeletal muscle. Development 124, 4729–4738.
Kablar, B., Krastel, K., Ying, C., Tapscott, S.J., Goldhamer, D.J., and Rudnicki,
M.A. (1999). Myogenic determination occurs independently in somites and
limb buds. Dev. Biol. 206, 219–231.
Kagey, M.H., Newman, J.J., Bilodeau, S., Zhan, Y., Orlando, D.A., van Ber-
kum, N.L., Ebmeier, C.C., Goossens, J., Rahl, P.B., Levine, S.S., et al.
(2010). Mediator and cohesin connect gene expression and chromatin archi-
tecture. Nature 467, 430–435.
Kelly, T.K., Miranda, T.B., Liang, G., Berman, B.P., Lin, J.C., Tanay, A., and
Jones, P.A. (2010). H2A.Z maintenance during mitosis reveals nucleosome
shifting on mitotically silenced genes. Mol. Cell 39, 901–911.
Koch, C.M., Andrews, R.M., Flicek, P., Dillon, S.C., Karao¨z, U., Clelland, G.K.,
Wilcox, S., Beare, D.M., Fowler, J.C., Couttet, P., et al. (2007). The landscape
of histone modifications across 1% of the human genome in five human cell
lines. Genome Res. 17, 691–707.
Lassar, A.B., Paterson, B.M., and Weintraub, H. (1986). Transfection of a DNA
locus that mediates the conversion of 10T1/2 fibroblasts to myoblasts. Cell 47,
649–656.
Lepikhov, K., and Walter, J. (2004). Differential dynamics of histone H3 meth-
ylation at positions K4 and K9 in the mouse zygote. BMC Dev. Biol. 4, 12.
Lin, J.C., Jeong, S., Liang, G., Takai, D., Fatemi, M., Tsai, Y.C., Egger, G.,
Gal-Yam, E.N., and Jones, P.A. (2007). Role of nucleosomal occupancy
in the epigenetic silencing of the MLH1 CpG island. Cancer Cell 12,
432–444.
MacIsaac, K.D., Lo, K.A., Gordon, W., Motola, S., Mazor, T., and Fraenkel, E.
(2010). A quantitative model of transcriptional regulation reveals the influence
of binding location on expression. PLoS Comput. Biol. 6, e1000773.
Maherali, N., Sridharan, R., Xie, W., Utikal, J., Eminli, S., Arnold, K., Stadtfeld,
M., Yachechko, R., Tchieu, J., Jaenisch, R., et al. (2007). Directly reprog-
rammed fibroblasts show global epigenetic remodeling and widespread tissue
contribution. Cell Stem Cell 1, 55–70.
Miele, A., and Dekker, J. (2009). Mapping cis- and trans- chromatin interaction
networks using chromosome conformation capture (3C). Methods Mol. Biol.
464, 105–121.
Pinset, C., Montarras, D., Chenevert, J., Minty, A., Barton, P., Laurent, C., and
Gros, F. (1988). Control of myogenesis in the mouse myogenic C2 cell line by
medium composition and by insulin: characterization of permissive and induc-
ible C2 myoblasts. Differentiation 38, 28–34.
Rada-Iglesias, A., Bajpai, R., Swigut, T., Brugmann, S.A., Flynn, R.A., and
Wysocka, J. (2011). A unique chromatin signature uncovers early develop-
mental enhancers in humans. Nature 470, 279–283.
Raney, B.J., Cline, M.S., Rosenbloom, K.R., Dreszer, T.R., Learned, K.,
Barber, G.P., Meyer, L.R., Sloan, C.A., Malladi, V.S., Roskin, K.M., et al.
(2011). ENCODE whole-genome data in the UCSC genome browser (2011
update). Nucleic Acids Res. 39(Database issue), D871–D875.
Rideout, W.M., 3rd, Eggan, K., and Jaenisch, R. (2001). Nuclear cloning and
epigenetic reprogramming of the genome. Science 293, 1093–1098.
Schmidt, D., Schwalie, P.C., Ross-Innes, C.S., Hurtado, A., Brown, G.D., Car-
roll, J.S., Flicek, P., and Odom, D.T. (2010). A CTCF-independent role for co-
hesin in tissue-specific transcription. Genome Res. 20, 578–588.Cell 147, 1283–1294, December 9, 2011 ª2011 Elsevier Inc. 1293
Schmitges, F.W., Prusty, A.B., Faty, M., Stu¨tzer, A., Lingaraju, G.M., Aiwazian,
J., Sack, R., Hess, D., Li, L., Zhou, S., et al. (2011). Histone methylation by
PRC2 is inhibited by active chromatin marks. Mol. Cell 42, 330–341.
Schreiber, E., Matthias, P., Mu¨ller, M.M., and Schaffner, W. (1989). Rapid
detection of octamer binding proteins with ‘mini-extracts’, prepared from
a small number of cells. Nucleic Acids Res. 17, 6419.
Stamatoyannopoulos, J.A., Sabo, P.J., Kuehn, M.S., Thurman, R., Johnson,
B.E., Johnson, E.M., Hua, C., Man, Y., Rosenzweig, E., Goldy, J., et al.
(2006). Genome-scale mapping of DNase I sensitivity in vivo using tiling DNA
microarrays. Nat. Methods 3, 511–518.
Takahashi, K., and Yamanaka, S. (2006). Induction of pluripotent stem cells
from mouse embryonic and adult fibroblast cultures by defined factors. Cell
126, 663–676.
Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K.,
and Yamanaka, S. (2007). Induction of pluripotent stem cells from adult human
fibroblasts by defined factors. Cell 131, 861–872.
Tapscott, S.J., Lassar, A.B., and Weintraub, H. (1992). A novel myoblast
enhancer element mediates MyoD transcription. Mol. Cell. Biol. 12, 4994–
5003.
Visel, A., Rubin, E.M., and Pennacchio, L.A. (2009). Genomic views of distant-
acting enhancers. Nature 461, 199–205.1294 Cell 147, 1283–1294, December 9, 2011 ª2011 Elsevier Inc.Wang, Z., Zang, C., Rosenfeld, J.A., Schones, D.E., Barski, A., Cuddapah, S.,
Cui, K., Roh, T.Y., Peng, W., Zhang, M.Q., and Zhao, K. (2008). Combinatorial
patterns of histone acetylations and methylations in the human genome. Nat.
Genet. 40, 897–903.
Weintraub, H., Tapscott, S.J., Davis, R.L., Thayer, M.J., Adam, M.A., Lassar,
A.B., and Miller, A.D. (1989). Activation of muscle-specific genes in pigment,
nerve, fat, liver, and fibroblast cell lines by forced expression of MyoD. Proc.
Natl. Acad. Sci. USA 86, 5434–5438.
Wolff, E.M., Byun, H.M., Han, H.F., Sharma, S., Nichols, P.W., Siegmund, K.D.,
Yang, A.S., Jones, P.A., and Liang, G. (2010). Hypomethylation of a LINE-1
promoter activates an alternate transcript of the MET oncogene in bladders
with cancer. PLoS Genet. 6, e1000917.
Xi, H., Shulha, H.P., Lin, J.M., Vales, T.R., Fu, Y., Bodine, D.M., McKay, R.D.,
Chenoweth, J.G., Tesar, P.J., Furey, T.S., et al. (2007). Identification and char-
acterization of cell type-specific and ubiquitous chromatin regulatory struc-
tures in the human genome. PLoS Genet. 3, e136.
You, J.S., Kelly, T.K., De Carvalho, D.D., Taberlay, P.C., Liang, G., and Jones,
P.A. (2011). OCT4 establishes and maintains nucleosome-depleted regions
that provide additional layers of epigenetic regulation of its target genes.
Proc. Natl. Acad. Sci. USA 108, 14497–14502.
